Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients
| Autor: | Massimo Caracciolo, Pierpaolo Correale, Carmelo Mangano, Giuseppe Foti, Carmela Falcone, Sebastiano Macheda, Maria Cuzzola, Marco Conte, Antonella Consuelo Falzea, Eleonora Iuliano, Antonella Morabito, Michele Caraglia, Nicola Polimeni, Anna Ferrarelli, Demetrio Labate, Marco Tescione, Laura Di Renzo, Gaetano Chiricolo, Lorenzo Romano, Antonino De Lorenzo |
|---|---|
| Přispěvatelé: | Caracciolo, M., Correale, P., Mangano, C., Foti, G., Falcone, C., Macheda, S., Cuzzola, M., Conte, M., Falzea, A. C., Iuliano, E., Morabito, A., Caraglia, M., Polimeni, N., Ferrarelli, A., Labate, D., Tescione, M., Di Renzo, L., Chiricolo, G., Romano, L., De Lorenzo, A. |
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine Adenosine Azithromycin Settore MED/49 Gastroenterology Lopinavir 0302 clinical medicine Enzyme Inhibitor Immunology and Allergy Medicine 030212 general & internal medicine Enzyme Inhibitors Tomography Original Research Mortality rate Middle Aged Prognosis Pathophysiology Anti-Bacterial Agents X-Ray Computed Hospitalization Female medicine.symptom Case-Control Studie Cytokine Release Syndrome Cytochrome P-450 CYP3A Inhibitor Human Hydroxychloroquine medicine.drug lcsh:Immunologic diseases. Allergy Adult medicine.medical_specialty Prognosi Immunology Inflammation COVID-19 SARS-CoV-2 Length of stay Aged Case-Control Studies Cytochrome P-450 CYP3A Inhibitors Heparin Humans Tomography X-Ray Computed 03 medical and health sciences Pharmacotherapy Immune system Internal medicine Anti-Bacterial Agent business.industry Case-control study medicine.disease COVID-19 Drug Treatment 030104 developmental biology lcsh:RC581-607 business Cytokine storm |
| Zdroj: | Frontiers in Immunology, Vol 12 (2021) Frontiers in Immunology |
| ISSN: | 1664-3224 |
| DOI: | 10.3389/fimmu.2021.613070 |
| Popis: | Lack of specific antiviral treatment for COVID-19 has resulted in long hospitalizations and high mortality rate. By harnessing the regulatory effects of adenosine on inflammatory mediators, we have instituted a new therapeutic treatment with inhaled adenosine in COVID-19 patients, with the aim of reducing inflammation, the onset of cytokine storm, and therefore to improve prognosis. The use of inhaled adenosine in COVID19 patients has allowed reduction of length of stay, on average 6 days. This result is strengthened by the decrease in SARS-CoV-2 positive days. In treated patients compared to control, a clear improvement in PaO2/FiO2 was observed together with a reduction in inflammation parameters, such as the decrease of CRP level. Furthermore, the efficacy of inhaled exogenous adenosine led to an improvement of the prognosis indices, NLR and PLR. The treatment seems to be safe and modulates the immune system, allowing an effective response against the viral infection progression, reducing length of stay and inflammation parameters. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|